Jack Cuzick
#60,693
Most Influential Person Now
British cancer researcher
Jack Cuzick's AcademicInfluence.com Rankings
Jack Cuzicklaw Degrees
Law
#1056
World Rank
#1359
Historical Rank
#570
USA Rank
Common Law
#10
World Rank
#11
Historical Rank
#4
USA Rank
Download Badge
Law
Why Is Jack Cuzick Influential?
(Suggest an Edit or Addition)According to Wikipedia, Jack Martin Cuzick is an American-born British academic, director of the Wolfson Institute of Preventive Medicine in London and head of the Centre for Cancer Prevention. He is the John Snow Professor of Epidemiology at the Wolfson Institute, Queen Mary University of London.
Jack Cuzick's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer (1997) (2362)
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer (2005) (2258)
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial (2002) (1902)
- Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial (2010) (1575)
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. (2010) (1458)
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
- Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies (1996) (1205)
- Overview of the European and North American studies on HPV testing in primary cervical cancer screening (2006) (1089)
- A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. (2015) (1068)
- Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. (1992) (1045)
- A breast cancer prediction model incorporating familial and personal risk factors (2004) (1037)
- A Wilcoxon-type test for trend. (1985) (968)
- A Wilcoxon-type test for trend. (1985) (883)
- Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. (1994) (877)
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. (2010) (865)
- Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women (1988) (842)
- Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease (2002) (781)
- Overview of the main outcomes in breast-cancer prevention trials (2003) (771)
- Multivariate generalizations of the proportional hazards model (1985) (761)
- First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial (2002) (727)
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. (2008) (687)
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer (2003) (684)
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. (2009) (673)
- Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. (2010) (666)
- Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. (2011) (666)
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. (2011) (658)
- Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. (2008) (644)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study (2008) (637)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Management of women who test positive for high-risk types of human papillomavirus: the HART study (2003) (600)
- The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women (2011) (581)
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older (2009) (578)
- Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. (2013) (552)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases (1986) (532)
- Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. (2010) (518)
- Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. (2007) (510)
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2010) (504)
- Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial (2014) (504)
- Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial (2002) (486)
- European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication (2012) (469)
- Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer (2008) (453)
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. (2012) (449)
- Spatial clustering for inhomogeneous populations (1990) (445)
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. (2006) (433)
- Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. (2008) (420)
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (2013) (398)
- PROGRESSIVE POTENTIAL OF MILD CERVICAL ATYPIA: PROSPECTIVE CYTOLOGICAL, COLPOSCOPIC, AND VIROLOGICAL STUDY (1986) (397)
- Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data (2009) (393)
- Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort (2012) (381)
- Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. (2011) (366)
- Prevention of colorectal cancer by once-only sigmoidoscopy (1993) (363)
- Prevention and early detection of prostate cancer. (2014) (357)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- Benefit of cervical screening at different ages: evidence from the UK audit of screening histories (2003) (351)
- Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. (2008) (343)
- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. (2013) (342)
- Human papillomavirus testing in primary cervical screening (1995) (340)
- Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. (2002) (334)
- Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. (1996) (333)
- Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial (2015) (327)
- Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. (1988) (325)
- Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. (2006) (323)
- Tamoxifen and breast density in women at increased risk of breast cancer. (2004) (323)
- Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. (2008) (306)
- Geographical and environmental epidemiology : methods for small-area studies (1997) (305)
- Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials (2007) (299)
- Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. (2004) (295)
- Adjusting for non-compliance and contamination in randomized clinical trials. (1997) (294)
- Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230) (2006) (290)
- Aspirin and cancer risk: a quantitative review to 2011. (2012) (289)
- HPV testing in primary screening of older women (1999) (288)
- Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
- Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial (2007) (278)
- The Sexual Activity Questionnaire: A measure of women's sexual functioning (1996) (277)
- Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. (2010) (271)
- Estimates of benefits and harms of prophylactic use of aspirin in the general population (2014) (270)
- Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. (2006) (269)
- Human papillomavirus genotype as a predictor of persistence and development of high‐grade lesions in women with minor cervical abnormalities (1996) (265)
- Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. (2005) (261)
- CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. (2012) (256)
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer (2010) (254)
- Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial (2017) (252)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (247)
- Comparison of Predictors for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears (2008) (239)
- Key steps for effective breast cancer prevention (2020) (237)
- Bilateral primary breast cancer: A prospective study of disease incidence (1984) (236)
- Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. (1996) (231)
- Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer (2006) (226)
- Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. (2006) (222)
- A systematic review of the role of human papillomavirus testing within a cervical screening programme. (1999) (221)
- Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer (2018) (215)
- Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). (2009) (213)
- Preventive therapy for breast cancer: a consensus statement. (2011) (212)
- Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer (2013) (211)
- Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. (1994) (206)
- Pancreatic cancer, alcohol, diabetes mellitus and gall‐bladder disease (1989) (203)
- EFFECT OF CIGARETTE SMOKING ON CERVICAL EPITHELIAL IMMUNITY: A MECHANISM FOR NEOPLASTIC CHANGE? (1988) (202)
- Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. (2009) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. (2013) (195)
- Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. (2007) (193)
- The Reliability of Dichotomous Judgments: Unequal Numbers of Judges per Subject (1979) (190)
- Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy (2016) (189)
- Comparing the performance of six human papillomavirus tests in a screening population (2013) (187)
- Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. (2004) (183)
- Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. (2008) (181)
- Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. (2008) (181)
- Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. (2008) (177)
- Psychosocial influences on older adults' interest in participating in bowel cancer screening. (2000) (174)
- Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis (2015) (171)
- Overview of the main outcomes in breast cancer prevention trials (2003) (170)
- Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death (2018) (169)
- Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study (2007) (165)
- Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study (2012) (165)
- Complex patterns of ETS gene alteration arise during cancer development in the human prostate (2008) (160)
- Breast cancer and hormonal contraceptives: further results (1996) (158)
- TAMOXIFEN AND CONTRALATERAL BREAST CANCER (1985) (157)
- Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort (2015) (156)
- A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions (2000) (154)
- Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer (1992) (154)
- HPV-FASTER: broadening the scope for prevention of HPV-related cancer (2016) (153)
- Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. (1998) (152)
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial (2016) (150)
- Psychosexual trauma of an abnormal cervical smear (1988) (150)
- Aromatase inhibitors for breast cancer prevention. (2005) (149)
- Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening (1998) (148)
- A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. (1987) (146)
- Long-term outcome among men with conservatively treated localised prostate cancer (2006) (143)
- Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. (2013) (140)
- Germline mutations of the CDKN2 gene in UK melanoma families. (1997) (139)
- Ingested arsenic, keratoses, and bladder cancer. (1992) (137)
- Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. (2003) (137)
- New technologies and procedures for cervical cancer screening. (2012) (137)
- Chapter 10: New dimensions in cervical cancer screening. (2006) (136)
- Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease (2014) (135)
- A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in women (2015) (135)
- Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women (2000) (134)
- A population‐based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination (2013) (134)
- Cervical screening by visual inspection, HPV testing, liquid‐based and conventional cytology in Amazonian Peru (2007) (134)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (134)
- Screening and adenocarcinoma of the cervix (2009) (131)
- SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. (2010) (131)
- The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC‐US or LSIL cervical cytology: A meta‐analysis of the diagnostic accuracy (2013) (131)
- Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study (2009) (130)
- Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. (2011) (129)
- Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density (2018) (128)
- Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort (2015) (127)
- A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. (2005) (126)
- Cervical cancer screening following prophylactic human papillomavirus vaccination. (2008) (125)
- Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. (2001) (124)
- Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial (2020) (124)
- Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trial (2000) (123)
- Correcting for non‐compliance bias in case–control studies to evaluate cancer screening programmes (2002) (120)
- A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial (2010) (119)
- Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. (2001) (118)
- Clinical and epidemiological issues in mammographic density (2012) (117)
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (117)
- DNA adducts in different tissues of smokers and non‐smokers (1990) (117)
- Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort (2013) (116)
- Naevi and pigmentary characteristics as risk factors for melanoma in a high‐risk population: A case‐control study in new South Wales, Australia (1996) (116)
- THE PREVENTION OF BREAST CANCER (1986) (115)
- Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. (2000) (113)
- Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study. (2004) (113)
- The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. (1998) (112)
- Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). (2008) (112)
- Accelerated decline in cervical cancer mortality in England and Wales (1995) (111)
- International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patients (2007) (108)
- Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer (2008) (107)
- Cervical Carcinoma and Sexual Behavior: Collaborative Reanalysis of Individual Data on 15,461 Women with Cervical Carcinoma and 29,164 Women without Cervical Carcinoma from 21 Epidemiological Studies (2009) (107)
- Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer (2013) (106)
- Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study (2014) (105)
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. (2015) (104)
- Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention (2012) (104)
- Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer (2018) (103)
- American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. (2009) (103)
- Overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in breast cancer. (1987) (103)
- Geographical and Environmental Epidemiology (1996) (101)
- Nucleic acid tests for the detection of alpha human papillomaviruses. (2012) (101)
- Detection of high‐risk HPV types by the hybrid capture 2 test (2001) (100)
- Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome (2016) (100)
- How to evaluate emerging technologies in cervical cancer screening? (2009) (99)
- Forest plots and the interpretation of subgroups (2005) (98)
- A strong law for weighted sums of i.i.d. random variables (1995) (98)
- Design of a multicentre randomised trial to evaluate flexible sigmoidoscopy in colorectal cancer screening (2001) (97)
- Electropotential measurements as a new diagnostic modality for breast cancer (1998) (96)
- Medicinal arsenic and internal malignancies. (1982) (95)
- Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of αvβ6 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence (2013) (95)
- Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study (2016) (95)
- Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era (2017) (94)
- Multiple myeloma--a case-control study. (1988) (94)
- Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. (2006) (93)
- Semiparametric additive regression (1992) (92)
- Radiation-induced myelomatosis. (1981) (90)
- Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. (2003) (90)
- Long‐term follow‐up of cervical abnormalities among women screened by HPV testing and cytology—Results from the Hammersmith study (2008) (90)
- Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK (2010) (89)
- The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. (1985) (88)
- Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study (2012) (88)
- Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials (2016) (88)
- Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 (2018) (88)
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. (2009) (86)
- Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction (2018) (86)
- How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? (1993) (85)
- Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979. (1984) (85)
- Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). (2003) (83)
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial (2019) (83)
- Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing (2011) (82)
- Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi (1998) (82)
- Determinants of percentage and area measures of mammographic density. (2009) (81)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting (2007) (80)
- Susceptibility to human papillomavirus‐associated cervical intra‐epithelial neoplasia is determined by specific HLA DR‐DQ alleles (1996) (80)
- HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. (2007) (80)
- Cancer Prevention: Obstacles, Challenges and the Road Ahead. (2016) (79)
- Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women (2014) (79)
- HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis (2009) (79)
- Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas (2011) (77)
- Once-only sigmoidoscopy. (1999) (77)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (77)
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer (2019) (75)
- Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intent (2008) (75)
- Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. (2009) (73)
- Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. (2011) (72)
- Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer (2008) (71)
- Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic (2014) (71)
- Effect of smoking cessation on cervical lesion size (1996) (71)
- Case-control study of risk factors for cervical intraepithelial neoplasia in young women. (1990) (70)
- Mild cervical dyskaryosis: safety of cytological surveillance (1992) (70)
- Joint Continuity of Gaussian Local Times (1982) (70)
- Preventive therapy for cancer. (2017) (70)
- Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On (2015) (70)
- HPV DNA testing in cervical cancer screening: from evidence to policies. (2006) (69)
- Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial (2014) (69)
- Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement (2009) (69)
- Breast cancer risk feedback to women in the UK NHS breast screening population (2016) (69)
- Association Between HLA DQBl * 03 and Cervical Intra-epithelial Neoplasia (1995) (68)
- Estimates of benefits and harms of prophylactic use of aspirin in the general population. (2015) (68)
- Human papillomavirus testing for primary cervical cancer screening. (2000) (68)
- Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I (2014) (68)
- Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark (2015) (68)
- Validation of a DNA methylation HPV triage classifier in a screening sample (2016) (68)
- Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? (2006) (68)
- A comparison of five methods of measuring mammographic density: a case-control study (2018) (66)
- Risk factors for invasive cervix cancer in young women. (1996) (65)
- [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. (2012) (65)
- Genetic heterogeneity in familial malignant melanoma. (1994) (64)
- Use of the concordance index for predictors of censored survival data (2016) (63)
- Recommendations for cervical cancer prevention in Asia Pacific. (2008) (63)
- Mutation testing in melanoma families: INK4A, CDK4 and INK4D (1999) (63)
- Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study (2010) (63)
- Risk of ocular melanoma in relation to cutaneous and IRIS naevi (1995) (62)
- Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. (2011) (61)
- Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials (2016) (61)
- IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole (2008) (60)
- APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. (2013) (60)
- HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology (2013) (59)
- Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom (2002) (59)
- Screening for cancer: future potential (1999) (59)
- Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. (2015) (58)
- Markers for the identification of late breast cancer recurrence (2015) (58)
- Efficient Estimates in Semiparametric Additive Regression Models with Unknown Error Distribution (1992) (57)
- Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. (2009) (57)
- Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. (2015) (57)
- Role of Aspirin in Cancer Prevention (2013) (57)
- Chemoprevention of breast cancer with tamoxifen. (1996) (56)
- The effect of stopping smoking on cervical Langerhans'cells and lymphocytes (2001) (55)
- Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone (2019) (55)
- Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. (2014) (55)
- New dimensions in cervical cancer screening (2006) (54)
- Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population (2014) (54)
- PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. (2016) (53)
- Small-area studies: purpose and methods (1996) (53)
- Results of the mrc myelomatosis trials for patients entered since 1980 (1988) (53)
- Long‐term prognostic value of serum β2 microglobulin in myelomatosis (1990) (52)
- Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. (1992) (52)
- Estimating the effect of treatment in a proportional hazards model in the presence of non‐compliance and contamination (2007) (52)
- Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16 (2015) (52)
- Long‐term survival in myelomatosis; A REPORT TO THE MRC WORKING PARTY ON LEUKAEMIA IN ADULTS (1982) (52)
- The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case–control study (2016) (52)
- Effect of smoking cessation on cervical lesion size (1996) (51)
- Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view (2008) (51)
- A Population-Based Evaluation of Cervical Screening in the United States: 2008–2011 (2013) (51)
- Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (51)
- Could HPV testing become the sole primary cervical screening test? (2002) (51)
- Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions: A Systematic Review and Meta-analysis. (2016) (51)
- Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males (2011) (50)
- Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial (2018) (49)
- Need for expanded HPV genotyping for cervical screening☆ (2016) (49)
- Psychological impact of colorectal cancer screening. (2003) (48)
- A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes (2014) (48)
- The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status (2015) (48)
- Single blind, randomised trial of efficacy and acceptability of oral picolax versus self administered phosphate enema in bowel preparation for flexible sigmoidoscopy screening. (2000) (48)
- The prevention, detection, and management of breast cancer (2006) (48)
- Abstract S1-7: Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. (2010) (48)
- A CENTRAL LIMIT THEOREM FOR THE NUMBER OF ZEROS OF A STATIONARY GAUSSIAN PROCESS (1976) (47)
- Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions (2014) (47)
- The EM Algorithm for Cox's Regression Model Using Glim (1985) (47)
- Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading (2007) (47)
- PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. (2010) (47)
- Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. (2006) (46)
- Increasing trends of multiple myeloma mortality in England and Wales; 1950-79: are the changes real? (1982) (46)
- Screening for cervical cancer (1998) (45)
- Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia (2019) (45)
- ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer (2009) (45)
- Five cases of coexistent primary ocular and cutaneous melanoma. (1993) (45)
- Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer (2012) (45)
- Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests) (2016) (45)
- EUROGIN 2008 roadmap on cervical cancer prevention (2009) (45)
- A prospective study of plasma prolactin levels and subsequent risk of breast cancer (1981) (44)
- Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies (2009) (44)
- Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants (2019) (43)
- Rank tests for association with right censored data (1982) (43)
- International variations and temporal trends in mortality from multiple myeloma (1983) (43)
- Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type (1997) (43)
- Prevention of breast cancer in the context of a national breast screening programme (2012) (42)
- Gardasil 9 joins the fight against cervix cancer (2015) (42)
- The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data (1982) (42)
- Perimenopausal risk factors and future health. (2011) (42)
- p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer (2009) (42)
- Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer (2013) (41)
- Epidemiology of breast cancer--selected highlights. (2003) (41)
- Vascular effects of aromatase inhibitors: Data from clinical trials (2005) (41)
- PALMAR KERATOSES AND CANCERS OF THE BLADDER AND LUNG (1984) (41)
- The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States (2014) (40)
- Assessing and managing breast cancer risk: clinicians' current practice and future needs. (2014) (40)
- An explanation for the problem of false‐negative cervical smears (1989) (39)
- Role of HPV testing in clinical practice. (2002) (39)
- Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. (2009) (39)
- Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. (2009) (39)
- ASYMPTOTIC PROPERTIES OF CENSORED LINEAR RANK TESTS (1985) (39)
- Sequence variation in the capsid protein genes of human papillomavirus type 16. (1994) (39)
- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
- Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends (2016) (38)
- Impact of preventive therapy on the risk of breast cancer among women with benign breast disease (2015) (37)
- Human papillomavirus infection of the prostate. (1995) (37)
- Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study (2020) (37)
- Performance of the Abbott RealTime high‐risk HPV test in women with abnormal cervical cytology smears (2010) (37)
- Cytokeratin expression and acetowhite change in cervical epithelium. (1994) (36)
- Prevention of breast cancer (1992) (36)
- Long-term cervical cancer prevention strategies across the globe. (2010) (36)
- Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data (2006) (36)
- Breast surgery in the ‘Arimidex, Tamoxifen Alone or in Combination’ (ATAC) trial (2004) (36)
- Trends in cervix cancer mortality. (1988) (36)
- Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. (2013) (36)
- Methods for the assessment of disease clusters (1996) (36)
- Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis. (2000) (36)
- A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model (2019) (35)
- Predictive algorithms for adjuvant therapy: TransATAC (2011) (35)
- Update on breast cancer risk prediction and prevention (2015) (35)
- A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies (2017) (35)
- A case–control study to estimate the impact on breast cancer death of the breast screening programme in Wales (2004) (35)
- Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer (2012) (35)
- Breast density and breast cancer risk factors in a high-risk population. (2003) (35)
- Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico (2019) (35)
- A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers☆ (2014) (34)
- Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. (2008) (34)
- Screening performance of abbreviated versions of the UPSIT smell test (2018) (34)
- Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention (2014) (34)
- Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) (2017) (34)
- Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial (2015) (34)
- Which patients are cured of breast cancer? (1984) (33)
- A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales (2004) (33)
- Use of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: An Overview of the Randomized Trials. (2009) (33)
- Primary endpoints for randomised trials of cancer therapy (2008) (33)
- HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier. (2015) (33)
- A Brief Review of the International Breast Cancer Intervention Study (IBIS), the Other Current Breast Cancer Prevention Trials, and Proposals for Future Trials a (2001) (33)
- Vitamin A, vitamin E and the risk of cervical intraepithelial neoplasia. (1990) (33)
- A case-control study of cervix cancer in Singapore. (1989) (32)
- Radiotherapy for breast cancer, the TARGIT-A trial (2014) (32)
- Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome (2007) (32)
- 32P-postlabelling analysis of DNA from human tissues. (1992) (32)
- Local Nondeterminism and the Zeros of Gaussian Processes (1978) (31)
- Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer (2015) (31)
- The prognostic value of Ki-67 expression in penile squamous cell carcinoma (2012) (31)
- The Parkinson's Disease Mendelian Randomization Research Portal (2019) (31)
- iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management (2016) (31)
- Performance of the Xpert HPV assay in women attending for cervical screening (2015) (31)
- Hormone replacement therapy and the risk of breast cancer. (2008) (31)
- Quantification of 7-methyldeoxyguanosine using immunoaffinity purification and HPLC with electrochemical detection. (1993) (31)
- Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. (2015) (31)
- A method for analysing case-control studies with ordinal exposure variables. (1985) (30)
- Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2006) (30)
- A case–control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density (2019) (30)
- Light chain isotype‐associated suppression of normal plasma cell numbers in patients with multiple myeloma (1979) (30)
- The retinoblastoma protein/p16INK4A pathway but not p53 is disrupted by human papillomavirus in penile squamous cell carcinoma (2011) (30)
- Boundary crossing probabilities for stationary Gaussian processes and Brownian motion (1981) (30)
- Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer (2006) (30)
- Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole (2012) (30)
- A breast cancer prediction model incorporating familial and personal risk factors (2012) (30)
- Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam) (2010) (30)
- What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420) (2020) (30)
- Treatment of DCIS--results from clinical trials. (2003) (29)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs’ attitudes (2017) (29)
- Risk Factors for High-Risk Human Papillomavirus Infection and Cofactors for High-Grade Cervical Disease in Peru (2011) (29)
- Possible cofactors in the etiology of cervical intraepithelial neoplasia. An immunopathologic study. (1989) (28)
- Prognostic factors in non-Hodgkin's lymphoma: the importance of symptomatic stage as an adjunct to the Kiel histopathological classification. (1983) (28)
- Prediction of reader estimates of mammographic density using convolutional neural networks (2019) (28)
- Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region☆ (2016) (28)
- Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer (2012) (28)
- Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. (2016) (28)
- Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial (2012) (28)
- Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK (2014) (28)
- Human papillomavirus testing for triage of women with low‐grade squamous intraepithelial lesions (2013) (27)
- Performance and Diagnostic Accuracy of a Urine-Based Human Papillomavirus Assay in a Referral Population (2017) (27)
- The low risk of precancer after a screening result of human papillomavirus‐negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management (2014) (27)
- Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation (2016) (27)
- Systematic review and meta-analysis of the association between Epstein–Barr virus, multiple sclerosis and other risk factors (2020) (27)
- Human papillomavirus testing 2007–2012: Co‐testing and triage utilization and impact on subsequent clinical management (2015) (27)
- Future possibilities in the prevention of breast cancer: Breast cancer prevention trials (2000) (26)
- Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial (2007) (26)
- A trial of human alpha interferon as an adjuvant agent in breast cancer after loco-regional recurrence. (1987) (26)
- The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data (2003) (26)
- Hormone replacement therapy and biological aggressiveness of breast cancer (1997) (26)
- Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. (2019) (26)
- Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. (2016) (26)
- Clinical Validation of the BD Onclarity™ HPV Assay Using a Non-Inferiority Test (2015) (25)
- Photoadaptation to ultraviolet (UV) radiation in vivo: photoproducts in epidermal cells following UVB therapy for psoriasis (2000) (25)
- On random Fourier series (1980) (25)
- An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent (2011) (25)
- Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. (2006) (25)
- Outcome measures in clinical trials of treatments for acute severe haemorrhage (2018) (25)
- Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer (2014) (24)
- Background risk of breast cancer and the association between physical activity and mammographic density (2015) (24)
- Evaluation of prediagnostic prostate‐specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively (2011) (24)
- Some Local Properties of Gaussian Vector Fields (1978) (24)
- Feasibility study of adjustment for contamination and non‐compliance in a prostate cancer screening trial (2007) (24)
- progressive Potential of Mild Cervical Atypia : Prospective Cytological, Colposcopic, and Virologic Study (1987) (24)
- Significant differences in UK and US female bone density reference ranges (2010) (24)
- Daily patterns of asthma in New York City and New Orleans: an epidemiologic investigation. (1983) (24)
- Concurrence of multiple human papillomavirus infections in a large US population-based cohort. (2014) (24)
- Effi cacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia : a randomised controlled trial (2010) (24)
- Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials (2017) (23)
- A brief review of the current breast cancer prevention trials and proposals for future trials. (2000) (23)
- Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial (2015) (23)
- Routine audit of large-scale cervical cancer screening programs. (2008) (23)
- The use of cervicography in a primary screening service. (1991) (23)
- Radiotherapy for breast cancer. (2005) (23)
- Routine audit is an ethical requirement of screening (2001) (23)
- A concordance index for matched case–control studies with applications in cancer risk (2015) (23)
- Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. (2018) (23)
- Semi‐quantitative human papillomavirus DNA detection in the management of women with minor cytological abnormality (1994) (23)
- Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico (2017) (23)
- Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer (2005) (23)
- Background risk of breast cancer influences the association between alcohol consumption and mammographic density (2015) (22)
- Long-term Follow-up in Cancer Prevention Trials (It Ain't Over 'Til It's Over) (2010) (22)
- Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1 (2009) (22)
- Impact of chemotherapy regimens prior to endocrine therapy (2006) (22)
- A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. (2009) (22)
- Visual Inspection after Acetic Acid (VIA) Is Highly Heterogeneous in Primary Cervical Screening in Amazonian Peru (2015) (22)
- OC11. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II) (2008) (22)
- Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments (2019) (22)
- Risk Models for Breast Cancer and Their Validation (2019) (22)
- Multiple points of a Gaussian vector field (1982) (22)
- Oestrogen and breast cancer: results from the WHI trial. (2012) (22)
- Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake (2015) (21)
- Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping (2019) (21)
- Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping (2019) (21)
- A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (vtes) after 5 years' treatment (2006) (21)
- Cancer genetics clinics. (1996) (21)
- The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions (2006) (20)
- Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study (2012) (20)
- Linear relationship between DNA adducts in human lung and cigarette smoking. (1990) (20)
- DNA methylation gene-based models indicating independent poor outcome in prostate cancer (2014) (20)
- Is hormone replacement therapy safe for breast cancer patients? (2001) (20)
- Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor–Positive Lymph Node–Negative Early-Stage Breast Cancer (2016) (20)
- Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. (2011) (20)
- Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines (2016) (20)
- Continuation of the International Breast Cancer Intervention Study (IBIS). (1998) (20)
- Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia [corrected]. (1992) (20)
- Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II (2017) (20)
- The use of cervicography in a primary screening service (1991) (19)
- HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. (2017) (19)
- Impact of screening on cervical cancer incidence: A population‐based case–control study in the United States (2019) (19)
- The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. (2007) (19)
- Cervical excisional treatment of young women: a population-based study. (2014) (19)
- DNA methylation of PITX2 predicts poor survival in men with prostate cancer. (2014) (19)
- Further analysis of the ARTISTIC trial. (2009) (19)
- A simple frailty model for family studies with covariates. (1994) (19)
- HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. (2016) (19)
- Laws of Large Numbers for Quadratic Forms, Maxima of Products and Truncated Sums of I.I.D. Random Variables (1995) (19)
- Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer (2020) (19)
- Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC (2017) (19)
- Trends in Cancer Incidence and Mortality (1995) (18)
- A Randomized Comparison of Different Vaginal Self-sampling Devices and Urine for Human Papillomavirus Testing—Predictors 5.1 (2021) (18)
- Breast cancer prevention in the developing world (2010) (18)
- THYROID DISEASE AND BREAST CANCER (1981) (18)
- A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population—PREDICTORS 4 (2016) (18)
- Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears (2003) (18)
- The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. (2002) (18)
- Preventing invasive breast cancer using endocrine therapy (2017) (17)
- Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer (2006) (17)
- 10-year analysis of the ATAC trial: wrong conclusion? – Authors' reply (2011) (17)
- Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing (2017) (17)
- Interaction, subgroup analysis and sample size. (1999) (17)
- Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. (2016) (17)
- Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease? (2016) (17)
- Molecular progression to cervical precancer, epigenetic switch or sequential model? (2018) (16)
- Anal cancer and marital status (1990) (16)
- Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK (2018) (16)
- Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer (2010) (16)
- A comparison of four cytological sampling techniques in a genitourinary medicine clinic. (1990) (16)
- Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer (2015) (16)
- Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. (2012) (16)
- Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews (2018) (15)
- Natural history of cervical human papillomavirus (2001) (15)
- Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom) (2020) (15)
- Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively (2018) (15)
- International Time Trends for Multiple Myeloma (1990) (15)
- Chemoprevention of breast cancer (2006) (15)
- Response and resistance to the endocrine prevention of breast cancer. (2008) (15)
- Comparison of four cytologic sampling techniques in a large family planning center. (1993) (15)
- Continuity of Gaussian Local Times (1982) (15)
- The Parkinson’s Disease Mendelian Randomization Research Portal (2019) (14)
- The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective (2007) (14)
- Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk (2020) (14)
- A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors (2016) (14)
- Human papilloma virus genotyping for the cross‐sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more (2018) (14)
- Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program (2015) (14)
- Conditions for Finite Moments of the Number of Zero Crossings for Gaussian Processes (1975) (14)
- Identifying clinically relevant prognostic subgroups in node-positive postmenopausal HR+ early breast cancer patients treated with endocrine therapy: A combined analysis of 2,485 patients from ABCSG-8 and ATAC using the PAM50 risk of recurrence (ROR) score and intrinsic subtype. (2013) (14)
- The detection of adducts in human cervix tissue DNA using 32P-postlabelling: a study of the relationship with smoking history and oral contraceptive use. (1994) (13)
- The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin? (2021) (13)
- Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool (2019) (13)
- Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study (2013) (13)
- Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico (2016) (13)
- Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial (2019) (13)
- Progress in preventive therapy for cancer: a reminiscence and personal viewpoint (2018) (13)
- Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer (2017) (13)
- Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico (2016) (13)
- International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. (2009) (13)
- Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. (1990) (12)
- Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results from the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. (2009) (12)
- General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey (2016) (12)
- Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. (2020) (12)
- A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (12)
- Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study (2020) (12)
- Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (2010) (12)
- Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2020) (12)
- Effective methylation triage of HPV positive women with abnormal cytology in a middle‐income country (2020) (12)
- Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years (2020) (12)
- The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer (2007) (12)
- More on zidovudine in asymptomatic HIV infection. (1994) (12)
- Breast Cancer Prevention Trials (2007) (11)
- Immunoaffinity concentration of human lung DNA adducts using an anti-benzo[a]pyrene-diol-epoxide-DNA antibody. Analysis by 32P-postlabelling or ELISA. (1993) (11)
- Effect of early American results on patients in a tamoxifen prevention trial (IBIS) (1998) (11)
- Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors (2016) (11)
- S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study. (2011) (11)
- Semiautomated detection of human papillomavirus DNA of high and low oncogenic potential in cervical smears. (1994) (11)
- Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer. (2001) (11)
- Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment (2015) (11)
- Comprehensive control of human papillomavirus infections and related diseases. (2013) (11)
- Breast-Cancer Tumor Size and Screening Effectiveness. (2017) (11)
- The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing (2018) (11)
- A prospective study of urinary androgen levels and ovarian cancer (1983) (11)
- Chemoprevention of breast cancer — An update (1998) (11)
- UK flexible sigmoidoscopy screening trial: Compliance, yield and adverse effects (2000) (11)
- Systematic review and meta-analysis of the association between Epstein-Barr virus, Multiple Sclerosis, and other risk factors (2019) (10)
- Cervical screening in the United Kingdom. (1999) (10)
- Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. (2022) (10)
- The ATAC (‘rimidex’, amoxifen, lone or in ombination) trial in postmenopausal women with early breast cancer—Updated efficacy results based on a median follow-up of 47 months (2003) (10)
- Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study (2021) (10)
- Methods for investigating localized clustering of disease. Clustering methods based on k nearest neighbour distributions. (1996) (10)
- Tamoxifen and the factor V Leiden mutation. (2010) (10)
- Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry (2019) (10)
- Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis (1987) (10)
- Autoimmune disorders and multiple myeloma. (1989) (10)
- An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database (2005) (10)
- Adherence to a Diet and Exercise Weight Loss Intervention amongst Women at Increased Risk of Breast Cancer (2010) (10)
- The percentage of high‐grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death (2019) (10)
- Anal cancer and marital status. (1990) (10)
- The organization of cervical screening in general practice. (1988) (10)
- Treating Breast Cancer (2003) (10)
- Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. (2015) (9)
- Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions (2002) (9)
- Early stopping of clinical trials (2005) (9)
- Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions. (2017) (9)
- Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women (2021) (9)
- Estrogen deprivation for breast cancer prevention. (2007) (9)
- Clinical follow-up practices after cervical cancer screening by co-testing: A population-based study of adherence to U.S. guideline recommendations (2021) (9)
- Mammographic dysplasia as entry criterion for breast cancer prevention trials (1991) (9)
- Update on new studies in Europe (2002) (9)
- Abstract P2-10-15: Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study (2012) (9)
- The UK breast-screening programme should start at age 47 years (2003) (9)
- Hormone replacement therapy and ovarian cancer. (1991) (9)
- Prognostic value of a cell cycle progression score for men with prostate cancer. (2014) (9)
- Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial (2021) (9)
- Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel. (2022) (9)
- Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort (2010) (9)
- The assessment of subgroups in clinical trials. (1982) (9)
- ER and HER 2 expression are positively correlated in HER 2 non-overexpressing breast cancer (2016) (9)
- Palmar keratoses and internal malignancy (1983) (8)
- Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates? (2012) (8)
- What is the Right Age for Cervical Cancer Screening? (2010) (8)
- A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo - a substudy for IBIS I Breast Cancer Prevention Trial. (2013) (8)
- Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions (2017) (8)
- Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. (1987) (8)
- Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ (2018) (8)
- Increase in Serum Total IGF-I and Maintenance of Free IGF-I Following Intentional Weight Loss in Pre-menopausal Women at Increased Risk of Breast Cancer (2010) (8)
- Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna® (2021) (8)
- Value of Phenotypic and Single-Nucleotide Polymorphism Panel Markers in Predicting the Risk of Breast Cancer (2013) (8)
- Combined Use Of Cytology, P16 Immunostaining And Genotyping For Triage Of Women Positive For High Risk Human Papillomavirus At Primary Screening. (2020) (8)
- Differing Perspectives on Breast Cancer Chemoprevention. (2016) (8)
- Palmar keratoses in family members of individuals with bladder cancer. (1990) (8)
- Dementia risk in a diverse population: A single-region nested case-control study in the East End of London (2022) (8)
- Event-based analysis times for randomised clinical trials (2001) (8)
- A case-control study to evaluate the impact of the breast screening programme on mortality in England (2020) (8)
- Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States. (2021) (8)
- Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer (2018) (8)
- 54O_PRCOMPARISON OF FIVE DIFFERENT SCORES FOR THE PREDICTION OF LATE RECURRENCE FOR OESTROGEN RECEPTOR-POSITIVE BREAST CANCER (2013) (8)
- Time to consider HPV testing in cervical screening. (2001) (8)
- Adjuvant use of anastrozole in breast cancer. (2004) (7)
- Breast surgery in the ATAC trial: women from the United States are more likely to have mastectomy. (2002) (7)
- Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). (2014) (7)
- 0130 Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population (2009) (7)
- Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. (2005) (7)
- Cervical smears following laser treatment. Comparison of Cervex brush versus Cytobrush-Ayre spatula sampling. (1991) (7)
- Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study (2019) (7)
- Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds (2018) (7)
- Effect of an Aromatase Inhibitor on Bone Mineral Density and Bone Turnover Markers: 2 year Results of the 'Arimidex' (Anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial (2006) (7)
- Preventive Therapy for Breast Cancer (2012) (7)
- Drop-outs in tamoxifen prevention trials (1999) (7)
- Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia (2019) (7)
- Abstract P5-13-03: The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial (2010) (7)
- Methodologic issues in the chemoprevention of breast cancer. (1995) (6)
- A review of semi-parametric models for life histories. (1984) (6)
- Assessing risk for breast cancer (2008) (6)
- A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States (2020) (6)
- The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer (2010) (6)
- HPV in cervical smears (1992) (6)
- Measurement challenge: protocol for international case–control comparison of mammographic measures that predict breast cancer risk (2019) (6)
- Re: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. (2001) (6)
- Interdisciplinary Approaches to COVID-19. (2021) (6)
- Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. (2020) (6)
- The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies (2021) (6)
- Breast density predicts endocrine treatment outcome in the adjuvant setting (2012) (6)
- Aromatase inhibitors in early breast-cancer treatment: The story so far. (2008) (6)
- Ovarian cancer screening: UKCTOCS trial (2016) (6)
- Prolaris: A novel genetic test for prostate cancer prognosis. (2013) (6)
- P4-11-07: Feasibility and Acceptability of Offering Breast Cancer Risk Estimation in the Context of the UK National Health Service Breast Cancer Screening Programme: A New Paradigm for Cancer Prevention. (2011) (6)
- Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (6)
- In Regard to Vaidya et al. (2015) (5)
- A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers (2020) (5)
- Correction: Local Nondeterminism and the Zeros of Gaussian Processes (1987) (5)
- Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia (2017) (5)
- Predicting late recurrence in ER-positive breast cancer (2019) (5)
- Molecular epidemiology: carcinogens, DNA adducts, and cancer--still a long way to go. (1995) (5)
- Prognosis vs Treatment Interaction (2018) (5)
- Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score (2013) (5)
- COLPOSCOPY OF WOMEN WITH CERVICAL HPV TYPE 16 INFECTION BUT NORMAL CYTOLOGY (1987) (5)
- Health Technology assessment Report: Ricerca del dna di papillomavirus umano (HPV) come test primario per lo screening dei precursori del cancro del collo dell'utero. (2012) (5)
- SNPs for breast cancer risk assessment (2017) (5)
- The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions (2004) (5)
- Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. (2019) (5)
- Keynote comment: Chemoprevention of cancer--time to catch up with the cardiologists. (2006) (5)
- Is overall survival an appropriate endpoint in early breast cancer studies? Data from the ATAC study at 100-month median follow-up (2008) (5)
- Cooperative breast cancer trials organized by the United Kingdom co‐ordinating committee on cancer research (1994) (5)
- A brief review of the breast cancer prevention trials. (2000) (5)
- Avoidance of premature death: a new definition for the proportion cured. (2002) (5)
- Letrozole or tamoxifen in early breast cancer. (2006) (5)
- Role of quantitative p 16 ( INK 4 A ) mRNA assay and digital reading of p 16 ( INK 4 A ) immunostained sections in diagnosis of cervical intraepithelial (2018) (5)
- 283 UK Flexible Sigmoidoscopy Screening Trial: Colorectal Cancer Incidence and Mortality Rates at 11 Years After a Single Screening Examination (2010) (5)
- Frequency estimation from crossings of an unknown level (1980) (5)
- European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes (2019) (4)
- Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials (2016) (4)
- A case–control study to evaluate the impact of the breast screening programme on breast cancer incidence in England (2022) (4)
- A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk (2021) (4)
- International study into the use of intermittent therapy in prostate cancer (2005) (4)
- Tamoxifen for breast-cancer prevention (2003) (4)
- Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay (2019) (4)
- Controversies in Design and Interpretation of Adjuvant Clinical Trials (2010) (4)
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review (2018) (4)
- Interpreting the results of noninferiority trials—a review (2022) (4)
- Author response: Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death (2018) (4)
- Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial (2021) (4)
- Breast cancer screening--time to move forward. (2002) (4)
- The Hausdorff dimension of the level sets of a Gaussian vector field (1980) (4)
- MP79-17 VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT (2014) (4)
- Risk factors for melanoma: site variation in minimal erythema dose (1992) (3)
- The PROVENT study, a multicentre double blind placebo controlled randomised trial to evaluate the effects of vitamin D and aspirin on progression of low risk prostate cancer during active surveillance (2017) (3)
- P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial. (2011) (3)
- Undesirable Gynaecological and Operative Interventions during Treatment of Breast Cancer with Anastrozole and Tamoxifen (2010) (3)
- Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. (2013) (3)
- Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial (2020) (3)
- Duration of aromatase inhibitor treatment in breast cancer: the role of the 'carryover effect'. (2013) (3)
- Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease? (2013) (3)
- Abstract S3-01: EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer (br ca) patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the oncotype DX recurrence score (RS) (2016) (3)
- Re: Start of cheaper technique for breast cancer is delayed in UK despite adoption elsewhere (2015) (3)
- Prediction of Late Breast Cancer Recurrence by the ROR (PAM50) Score in Postmenopausal Women in the Transatac Cohort (2012) (3)
- Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials. (2014) (3)
- The role of human papillomavirus testing in cervical screening (2000) (3)
- Bone versus breast density (2006) (3)
- Viruses and cancer. (2000) (3)
- Using a convolutional neural network to predict readers' estimates of mammographic density for breast cancer risk assessment (2018) (3)
- The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study (2021) (3)
- SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATION (2009) (3)
- Overview of adjuvant radiotherapy for breast cancer. (1990) (3)
- Breast cancer screening—time to move forward Peter C Gøtzsche (2012) (3)
- Adjuvant treatment with tamoxifen (1996) (3)
- Prostate cancer prevention (2014) (3)
- Abstract P3-07-05: Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study (2020) (3)
- 20OANALYSIS OF MOLECULAR SCORES FOR THE PREDICTION OF DISTANT RECURRENCE ACCORDING TO BODY MASS INDEX AND AGE AT BASELINE (2014) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- Epidemiology of gynaecological cancer (2011) (3)
- Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1) (2008) (3)
- Medicinal drugs with hormonal activity as chemopreventive agents. (1996) (3)
- Methods for investigating localized clustering of disease. Cuzick-Edwards one-sample and inverse two-sampling statistics. (1996) (3)
- Use of LHRH-agonists as adjuvant therapy for breast cancer. (2008) (3)
- Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. (2018) (3)
- Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinomain situ: Results from the UK/ANZ DCIS trial (2016) (2)
- Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial (2006) (2)
- Reply to the letter to the editor 'the harms of low-dose aspirin prophylaxis are overstated' by P. Elwood and G. Morgan. (2015) (2)
- Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (2)
- Adjunctive testing by cytology, p16/Ki‐67 dual‐stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen‐positive women (2020) (2)
- Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry (2021) (2)
- UKCCCR Trial of tamoxifen and/or radiotherapy for DCIS (2001) (2)
- Multiple myeloma. (1994) (2)
- Disease progression as a predictor of overall survival in metastatic breast cancer: a meta-analysis (2008) (2)
- The use of adjuvant chemotherapy in the ATAC trial: Nationality correlates with the use of chemotherapy. (2004) (2)
- Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis (2019) (2)
- Estimating efficacy in trials with selective crossover (2017) (2)
- Treating Skin Cancer (2003) (2)
- Breast cancer chemoprevention (2011) (2)
- A frailty model for interaction between multiple events (2013) (2)
- Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen? (2007) (2)
- Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy (2021) (2)
- Application of a time-space clustering methodology to the assessment of acute environmental effects on respiratory illnesses. (1981) (2)
- Maximising information on smell, quantitative motor impairment and probable REM-sleep behaviour disorder in the prediction of Parkinson’s disease (2020) (2)
- Abstract S3-01: Breast cancer prevention using anastrozole in postmenopausal women at high risk (2013) (2)
- Comparison of side-effect profiles during active treatment versus follow-up in the International Breast Cancer Intervention Study I tamoxifen prevention trial (2007) (2)
- The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge (2022) (2)
- Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR+ breast cancer: A TransATAC study. (2015) (2)
- Breast Cancer Risk Stratification in Women of Screening Age: Incremental Effects of Adding Mammographic Density, Polygenic Risk and a Gene Panel (2021) (2)
- Atypical hyperplasia of the breast. (2015) (2)
- E01*PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies (2015) (2)
- Searching for clusters and associations in cancer epidemiology. (1985) (2)
- HPV testing in cervical screening (1998) (2)
- Updated survival results from the Zebra trial. (2002) (2)
- Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies. (2009) (2)
- PD-01.08 (2006) (2)
- Abstract GS6-01: Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy (2018) (2)
- DNA methylation testing with S5 for triage of high‐risk HPV positive women (2022) (2)
- RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer (2017) (2)
- Analysis of Trials with Treatment — Individual Interactions (1992) (2)
- External validation of a mammographic texture marker for breast cancer risk in a case–control study (2020) (2)
- Conjunctival melanoma in the atypical mole syndrome (AMS): 222 (1993) (2)
- HPV testing in cervical screening. (1998) (2)
- Abstract 662: Molecular characterisation ofERG,ETV-1andPTEN- gene loci identifies patients at low and high risk of death from prostate cancer (2010) (2)
- Benefit of double‐reading cytology smears as a triage strategy among high‐risk human papillomavirus–positive women in Mexico (2020) (2)
- The classic approach (2000) (2)
- Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer – A Retrospective Exploratory Analysis from the ATAC Trial. (2009) (2)
- The molecular landscape of genome instability in prostate cancer (PC) (2016) (2)
- PROCAS: Predicting Risk of Breast Cancer at Screening (2016) (1)
- Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. (2011) (1)
- ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer (2012) (1)
- Patient Designed Therapy Provides Possible “Natural” Selection Evidence for Testosterone as Differentiating Agent for High-Grade Prostate Cancer (2009) (1)
- Consistency of the S5 DNA methylation classifier in formalin‐fixed biopsies versus corresponding exfoliated cells for the detection of pre‐cancerous cervical lesions (2021) (1)
- Sequential power calculations in a recruitment phase of a multicentre trial – the experience of the ‘Arimidex (anastrozole), tamoxifen alone or in combination’ (ATAC) study. (2002) (1)
- Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors (2016) (1)
- Anastrozole for ductal carcinoma in situ (2003) (1)
- Riemann ₁-summability of independent, identically distributed random variables (1981) (1)
- Abstract P5-12-01: Predicting the effect of tamoxifen on the breast: Change in measures of breast density, serum markers and SNPs (2015) (1)
- Abstract GS4-04: Ten year results of the international breast cancer intervention study II (2020) (1)
- ALCOHOL AND BREAST CANCER (1982) (1)
- FAST TRACK EUROGIN 2008 roadmap on cervical cancer prevention (2009) (1)
- Abstract P4-11-16: Low serum adiponectin level is an independent risk factor of DCIS in postmenopausal women at increased risk of breast cancer (2015) (1)
- 0-105. Electropotential measurements as a new modality for breast cancer diagnosis: results from a prospective multicentre trial (1997) (1)
- Natural history of prostate cancer in a large cohort of untreated patients in the United Kingdom (2005) (1)
- Screening for colorectal cancer (1993) (1)
- Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) (2020) (1)
- Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (2021) (1)
- Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study. (2014) (1)
- Abstract PD1-08: Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis (2016) (1)
- t amoxifen and the Factor V l eiden Mutation (2010) (1)
- Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want? (2013) (1)
- Abstract P1-09-06: Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial (2017) (1)
- Breast density predicts endocrine treatment outcome in the adjuvant setting (2012) (1)
- Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study (2012) (1)
- Immunochemistry for p 16 , but not Rb or p 21 , is an independent predictor of prognosis in conservatively treated , clinically localised prostate cancer (2015) (1)
- One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study (2011) (1)
- ACOG Guidelines on Cervical Screening: A Step in the Right Direction (2010) (1)
- Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I (2014) (1)
- Cross-Strati fi cationandDifferential RiskbyBreast Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer (2016) (1)
- The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial (2008) (1)
- Internation breast cancer intervention study I: updated side effects analysis (2006) (1)
- Cervical screening. (1988) (1)
- Reply to M. Rosman et al (2010) (1)
- Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420) (2023) (1)
- Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011 (2012) (1)
- Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ (2018) (1)
- Genotyping for HPV 16 and HPV 18 in women with minor cervical 1 lesions : a systematic review and meta-analysis (2017) (1)
- Key steps for effective breast cancer prevention (2020) (1)
- Screening for Cervical Cancer (2012) (1)
- Interaction of statisticians with DMCs. (2005) (1)
- Correction: Rank Regression (1990) (1)
- Project 2: assessment of predictive value of new genetic variants (2016) (1)
- MP02-20 THE CCP SCORE PROVIDES SIGNIFICANT PROGNOSTIC INFORMATION IN GLEASON SCORE < 7 PATIENTS (2016) (1)
- Abstract P1-09-05: The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer. (2012) (1)
- Risk factors, early presentations, and clinical markers of Parkinson's disease in Primary Care in a diverse UK population (2021) (1)
- Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study. (2018) (1)
- Burden of Mycoplasma genitalium and Bacterial Coinfections in a Population-Based Sample in New Mexico (2021) (1)
- Erratum to ‘A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States’ [Gynecologic Oncology 159 (2020) 344–353] (2021) (1)
- Moment conditions for the existence and nonexistence of optimal stopping rules for _ (1979) (1)
- Abstract P4-09-02: Validation of iPrevent using the prospective family study cohort (ProF-SC) (2019) (1)
- Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS) (2016) (1)
- Advances in Preventive Therapy. (2009) (1)
- Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010 (2011) (1)
- Abstract P2-07-02: A newly derived combined clinical treatment score and immunohistochemical-4 prognostic tool (2019) (1)
- Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer. (2020) (1)
- P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. (2011) (1)
- Abstract PD4-1: Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis (2015) (1)
- Assessing opportunities for coordinated R&D in early cancer detection and management in Europe (2016) (1)
- Commentary on Terry et al., 10-Year Performance of Four Models of Breast Cancer Risk: A Validation Study. Lancet Oncol. 2019;20(4):504-17 (2019) (1)
- Reply: The value of case–control audits of screening (2004) (1)
- Breast cancer risk assessment and validation in The National Breast Screening Programme: PRoCAS – Predicting Risk of Cancer At Screening study (2009) (1)
- Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. (2014) (1)
- Prevention of breast cancer. (1992) (1)
- Proffered Paper: A comparison of four methods of mammographic density measurement in the UK Predicting Risk Of Cancer At Screening (PROCAS) study – on behalf of the PROCAS Study team (2016) (1)
- Epidemiology of breast cancer (2003) (1)
- Role of sun exposure in the induction and involution of naevi: a joint case-control study of melanoma in England and Australia (1997) (1)
- Abstract P2-09-03: Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC (2017) (1)
- Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 (2016) (1)
- Erratum: A Strong Law for Weighted Sums of I.I.D. Random Variables, J. Theor. Prob. 8, 625–636 (1995) (2001) (1)
- Abstract PD1-07: Mammographic density and SNPs add to Tyrer-Cuzick and Gail model breast cancer risk in a UK screening cohort (2016) (1)
- P2-12-01: Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study. (2011) (1)
- Chemoprevention of Breast Cancer (2006) (1)
- Ki-67 is an independent predictor of outcome in conservatively treated clinically localised prostate cancer (2008) (1)
- Counting processes and survival analysis. Thomas R. Fleming and David P. Harrington, Wiley, New York, 1991. no. of pages: xiii + 429. Price: £39.95. ISBN: 0-471-52218-X (1992) (1)
- Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial (2021) (1)
- The effect of intermittent versus continuous energy restriction on biomarkers of breast cancer risk. (2009) (1)
- A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies (2017) (0)
- P240 Computerized Quantification of Tumor Infiltrating Lymphocyte (TIL) as a prognostic and predictive factor in ductal carcinoma in situ: Results from the UK/ANZ DCIS randomized trial (2023) (0)
- Treating Gynaecological Tumours (2003) (0)
- Design and statistical considerations (2003) (0)
- Characteristics of carpal-tunnel syndrome in the ATAC trial. (2009) (0)
- Abstract P3-06-01: Nuclear β-catenin negativity predicts for late relapse in ER+, tamoxifen-treated breast cancer (2015) (0)
- Chapter 9 Chemoprevention (2007) (0)
- HPV Oncogenic mRNA testing for Cervical Cancer Screening ; Baseline and Longitudinal 2 Results from the CLEAR Study 3 4 (2014) (0)
- Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. (2018) (0)
- Screening for Cancers (2003) (0)
- Treating Tumours of the Respiratory System (2003) (0)
- Breast cancer prevention — history and new data (2006) (0)
- Comment on: Tamoxifen for the prevention of breast cancer : Current status of the national surgical adjuvant breast and bowel project P-1 study. Authors' reply (2006) (0)
- Current Breast Cancer Prevention Trials, and Proposals for Future Trialsa (2001) (0)
- 10-year results of the International Breast Cancer Intervention Study II (IBIS-II) (2020) (0)
- Testing in case-control studies with ordinal exposure variables. Response (1988) (0)
- Histological characteristics of localized DCIS: observations from the UKCCCR DCIS Trial (1999) (0)
- Prevention of breast cancer using aromatase inhibitors (2007) (0)
- Effect of intermittent versus continuous energy restriction on weight loss and breast cancer risk biomarkers (2010) (0)
- Impact of HPV testing in Opportunistic Cervical Screening: Support for Primary HPV Screening in the United States. (2023) (0)
- Examples of parametric distributions potentially fitted to the adjusted lifetime risk of the PROCAS study population (2016) (0)
- Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. (2011) (0)
- MP1-08 PATIENT AUA RISK CLASSIFICATION BASED ON COMBINED CLINICAL CELL CYCLE RISK (CCR) SCORE (2015) (0)
- Abstract P5-06-05: Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer (2020) (0)
- Replay to letter by Drs Gillis and Hole (1982) (0)
- Timing and severity of prominent side effects of anastrozole and tamoxifen (2008) (0)
- 8LBA Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: First prospective results from PROCAS (2014) (0)
- Use of LHRH-agonists as adjuvant therapy for breast cancer (2008) (0)
- 26: Progress in breast cancer prevention (2014) (0)
- P128 Nipple aspirate fluid (NAF) cytology in the IBIS-model prediction of breast cancer (BCA) risk (2015) (0)
- Letter to the editor (0)
- StudyAbnormal Smears: the Predictors 2 Women Cervical Intraepithelial Neoplasia in Comparison of Seven Tests for High-Grade (2012) (0)
- Chemoprevention: beyond tamoxifen (2005) (0)
- General practitioner attitudes towards prescribing tamoxifen for the primary prevention of breast cancer: Results of a vignette study (2016) (0)
- Cervical screening over 50: money well spent (2017) (0)
- (2019). Parkinson’s Disease Mendelian Randomization Research (2019) (0)
- RIEMANN 7VSUMMABILITY OF INDEPENDENT, IDENTICALLY DISTRIBUTED RANDOM VARIABLES (2010) (0)
- Should I be tested for cancer? Maybe not and here's why, H Gilbert Welch. University of California Press (2004), US$19·95 (£10·53, €15·02), pp 224, ISBN: 0 520 23976 8 (2005) (0)
- First Asia–Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) Meeting (2006) (0)
- Supplement II: Abstracts of the international symposium on Skin Carcinogenesis in man and in experimental models. Heidelberg, 29–31 October 1991 (pp S61–S88) (1991) (0)
- Screening for cervical cancer. (1998) (0)
- UK randomized controlled trial of ‘once only’ flexible sigmoidoscopy screening: Interim results (1998) (0)
- Session 5 S14. IBIS-I and ATAC trials. Update and implications for IBIS-II (2002) (0)
- 778PCOMBINED ANALYSIS OF AN RNA CELL CYCLE PROGRESSION (CCP) SCORE FOR PREDICTING PROSTATE CANCER DEATH IN TWO CONSERVATIVELY MANAGED NEEDLE BIOPSY COHORTS. (2014) (0)
- Session 10 S33. Mass screening by flexible sigmoidoscopy (2002) (0)
- Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. (2022) (0)
- Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial (2017) (0)
- Review Treatment of DCIS—results from clinical trials (2003) (0)
- Overview of adjuvant radiotherapy for breast cancer. (1988) (0)
- PSA testing for prostate cancer screening--authors' reply. (2015) (0)
- Abstract PD14-01: PD14-01 A model to assess the utility of risk-based screening algorithms (2023) (0)
- Corrigendum to “Vascular effects of aromatase inhibitors: Data from clinical trials” [J. Steroid Biochem. Mol. Biol. 95 (2005) 143–149] (2006) (0)
- A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (0)
- The atypical mole syndrome (AMS): what is the best definition of phenotype? (1993) (0)
- Abstract P5-06-04: Prognostic value of EndoPredict and Oncotype Recurrence Score according to patient's age (2020) (0)
- Treating Tumours of the Gastrointestinal Tract (2003) (0)
- Women with a positive HPV test can safely have yearly surveillance rather than immediate colposcopy (2004) (0)
- Approaches to Breast Cancer Prevention (1991) (0)
- Improved use of clinical variables for prognosis of distant recurrence in patients with ER+ breast cancer treated with 5 years endocrine therapy. (2016) (0)
- Progress in preventive therapy for cancer: a reminiscence and personal viewpoint (2018) (0)
- 66 Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis (2019) (0)
- Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
- Association between naevi, solar keratoses and melanoma: a case-control study of melanoma in New South Wales, Australia (1996) (0)
- Optimising classification of Parkinson’s disease based on motor, olfactory, neuropsychiatric and sleep features (2021) (0)
- WHAT OTHER JOURNALS ARE SAYING (1995) (0)
- EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II) (2014) (0)
- Comprehensive comparison of the performance of six prognostic signatures for oestrogen receptor positive breast cancer receiving endocrine treatment (2018) (0)
- Abstract IA6: Cell cycle progression genes differentiate indolent from aggressive prostate cancer (2012) (0)
- Breast cancer prevention: SERMs come of age (2013) (0)
- Estimating the Complier Average Causal Effect for Exponential Survival in the Presence of Mid-Trial Switching (2012) (0)
- SIMS three year study on statistics and environmental factors in health. Technical progress report No. 2 (1977) (0)
- Prevalence of Sexually Transmitted Infections and Coinfection in a Population-Based Sample of Women Attending Cervical Cancer Screening in New Mexico, United States of America (2016) (0)
- Measuring Cancer burden in prostatic needle core biopsies: Simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimise datasets. (2023) (0)
- Supplementary Material for: Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation (2016) (0)
- Endpoints for the evaluation of breast cancer treatments. (2014) (0)
- HORMONAL PREVENTION OF RECURRENCE AND NEW TUMOURS IN WOMEN WITH DCIS (2003) (0)
- Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing (2022) (0)
- Report on Sydney Breast Cancer Trials Symposium: prevention issues (2004) (0)
- Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer (2016) (0)
- HPV Vaccines Continue to Improve, But More Uptake Required (2015) (0)
- O-101 Effect of tamoxifen on serum lipid levels in women at increased risk of breast cancer (2007) (0)
- 53 INVITED Cervix Cancer Vaccination (2011) (0)
- Early Detection and Diagnosis Overview of the European and North American studies on HPV testing in primary cervical cancer screening (2006) (0)
- Germline mutations in the CDKN2 and CDK4 genes are rare in melanoma families in the UK (1997) (0)
- The Beijing Cochrane Workshop on Cervical Cancer Prevention: cytology versus HPV-based cervical cancer screening (2008) (0)
- Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years (2020) (0)
- A meta-analysis of endocrine therapy trials in early breast cancer (BC) evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal therapy in obese ER+ BC? (2013) (0)
- Colorectal Cancer (2021) (0)
- Abstract PD14-08: Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status (2022) (0)
- Abstract P4-11-19: Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER+ breast cancer (2015) (0)
- EMBASE search filter (2016) (0)
- Primary Screening by Human Papillomavirus Testing: Development, Implementation, and Perspectives (2020) (0)
- Abstract S5-03: Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1) (2017) (0)
- What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420) (2020) (0)
- Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]. (2021) (0)
- Updated survival analyses from the ZEBRA study: goserelin vs CMF in premenopausal women with node-positive breast cancer (2003) (0)
- Selecting women for breast cancer chemoprevention and what agents should be used (2012) (0)
- Systemic adjuvant therapies for early breast cancer: 15‐year results for recurrence and survival (2005) (0)
- Recurrence Score in women with hormone receptor positive lymph-node 2 negative early stage breast cancer (2016) (0)
- 1774: Predicting Disease Specific Survival at the Time of Diagnosis Utilizing Clinical Variables Integrated with Quantitative Immunofluorescence (2007) (0)
- Use of multiple Single Nucleotide Polymorphism (SNP) testing to predict breast cancer risk in a familial screening clinic (2016) (0)
- Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm (2021) (0)
- Breast cancer preventive effect of tamoxifen persists after discontinuation of therapy (2007) (0)
- MP1-10 VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER (2015) (0)
- Association of genetic variations for prediction of hot flushes in women taking tamoxifen for breast cancer prevention (2020) (0)
- Comment: Duplication of the Fusion of TMPRSS2 to ERG Sequences Identifies Fatal Human Prostate Cancer (2008) (0)
- Tamoxifen for breast-cancer prevention [3] (multiple letters) (2003) (0)
- Impact of Screening on Breast Cancer Mortality—Response (2016) (0)
- Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna® (2021) (0)
- Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP. (2019) (0)
- Symposium: Human papillomavirus and cervical cancer screening (2000) (0)
- Abstract S3-07: 16 year long-term follow-up of the IBIS-I breast cancer prevention trial (2015) (0)
- POD-04.07: A New Recurrent Chromosomal Translocation, T(4;6)(q22;q15), in Prostate Cancer (2009) (0)
- Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort (2015) (0)
- What Is the Value of the 21 Gene Recurrence Score in HER2-Negative Patients? Reply (2010) (0)
- Project 1: improvement of risk prediction algorithms for women at high risk of breast cancer (2016) (0)
- Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer (2018) (0)
- Androgen Receptor in Tumor and Stroma in Conservatively Treated Prostate Cancer (2012) (0)
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review. (2021) (0)
- Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk (2018) (0)
- Methodologic Aspects of Prevention Trials (1991) (0)
- Letters Regarding the TARGIT-A Trial: The Editor's Introduction (2015) (0)
- Use of doubly stochastic poisson processes in estimating health effects due to air pollution. [Effects of air pollution on incidence of acute respiratory diseases in New York City area] (1976) (0)
- Authors' Reply (1991) (0)
- CAN HPV BE THE SOLE PRIMARY CERVICAL CANCER SCREENING TEST? (2006) (0)
- IS THE INCIDENCE OF MULTIPLE-MYELOMA REALLY INCREASING (1981) (0)
- Comparison of StemPrintER, a novel biology-based genomic predictor of distant recurrence in breast cancer, with Oncotype DX in the TransATAC cohort. (2020) (0)
- Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping (2019) (0)
- Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping (2019) (0)
- Would Free Fatty Acids Enhance Treatment of Obesity (2007) (0)
- Authors' reply (1991) (0)
- Principles and Practice of“Critical Appraisal” (2003) (0)
- Global prevention and management of HPV related diseases : the pressing challenges and the compelling opportunities (2014) (0)
- Abstract P4-11-02: Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk (2018) (0)
- Abstract ED04-01: Breast cancer chemoprevention (2011) (0)
- Cross-Strati fi cation and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor – Positive Lymph Node – Negative Early-Stage Breast Cancer (2016) (0)
- Adjuvant use of anastrozole in breast cancer. Authors' reply (2004) (0)
- Overview of adjuvant radiotherapy for breast cancer. (1989) (0)
- Optimal timing and duration of the use of an aromatase inhibitor (Al) in the adjuvant treatment of postmenopausal hormone receptor-positive (HR+) breast cancer (BC) (2008) (0)
- Treating Cancers of the Eye and Associated Structures (2003) (0)
- 1070 Cervical cancer screening — status and perspectives (2003) (0)
- Treating Tumours of the Urogenital System (2003) (0)
- Does the effectiveness of cervical screening vary with age ? Evidence from a population-based case-control study of prospectively recorded data (2009) (0)
- DNA methylation gene-based models indicating independent poor outcome in prostate cancer (2014) (0)
- 10-year analysis of the ATAC trial: wrong conclusion? Reply (2011) (0)
- Risk factors. Introduction to Session 1 (2009) (0)
- S3 Prevention of Cancer: What's new (2005) (0)
- Selecting women for breast cancer chemoprevention and what agents should be used (2012) (0)
- Which patients are cured of breast cancer? (1984) (0)
- Abstract P5-18-08: Defining molecular signatures to personalise management of patients with early breast cancer (2019) (0)
- Practitioner attitudes towards prescribing tamoxifen for the primary prevention of breast cancer (2017) (0)
- between and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. (2007) (0)
- Treating Central Nervous System Tumours (2003) (0)
- EFFECT OF SMOKING CESSATION ON CERVICAL LESION SIZE. AUTHORS' REPLY (1996) (0)
- S32. Prostate cancer prevention by short-term antiandrogens: A novel strategy (2008) (0)
- Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420). (2023) (0)
- Abstract PS18-10: Intratumoural heterogeneity in PgR expression: Molecular and prognostic significance (2021) (0)
- Article: Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent. (2023) (0)
- Prognostic value of endopredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials. (2019) (0)
- Abstract P3-08-01: Prognostic performance of EndoPredict in invasive lobular carcinoma (2018) (0)
- Early stopping of clinical trials (Commentary) (2005) (0)
- Population-level impact of human papillomavirus vaccination (2020) (0)
- Impact of a panel of 88 SNPs on the risk of breast cancer in high risk women: Results from two randomised tamoxifen prevention trials (2016) (0)
- Summaries of Papers (1993) (0)
- Symposium: COGS International Scientific Seminar (2012) (0)
- The Predictive Power of Prostate Cancer Extent Measurements in a Large Watchful Waiting Cohort (2009) (0)
- MEDLINE search filter (2016) (0)
- E17. The prevention of breast cancer (2014) (0)
- PG 6.02 Preventing invasive breast cancer in women at high risk based on benign/in situ pathology (2015) (0)
- Selected Abstracts from the 3rd European Hereditary Tumour Group Meeting (EHTG 2018) (2019) (0)
- Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom) (2020) (0)
- Can HPV testing be the sole primary cervical screening modality (2010) (0)
- PROCAS two-page questionnaire (2016) (0)
- A comparison of five methods of measuring mammographic density: a case-control study (2018) (0)
- Eliminating Cervical Cancer: Novel Options in Vaccination and Screening (2012) (0)
- Abstract P4-08-02: Importance of adverse events during endocrine treatment for the prediction of late distant recurrences (2019) (0)
- Screening for cancer: future potential. (1999) (0)
- Mammographic breast density. (2007) (0)
- Naevi and Solar Keratoses as Risk Factors for Melanoma in Australia (1997) (0)
- Abstract P5-15-01: Participant-reported symptoms as predictors of long-term adherence of endocrine therapy in the International breast cancer intervention studies 2 (IBIS-2) (2018) (0)
- Inherited a nd A cquired R isk F actors f or V enous Thromboembolic D isease A mong W omen T aking T amoxifen t o Prevent B reast C ancer (2003) (0)
- Age dependence in cancers of the breast, ovary and endometrium. (1985) (0)
- The use of hormone replacement therapy for women with breast cancer: a trial in the advanced disease setting (1997) (0)
- The Value of Helicobacter Eradication in Long-term Aspirin Users (2018) (0)
- S21. Use of aromatase inhibitors in breast cancer prevention (2008) (0)
- Competing Risks for a Diagnosis of Invasive Breast Cancer-Reply. (2019) (0)
- Background risk of breast cancer and the association between physical activity and mammographic density (2015) (0)
- Session 5 Primary prevention of breast cancer I: Ovarian suppression and ablation in premenopausal women at risk (2004) (0)
- In reply [4] (2006) (0)
- The effect of intermittent v. chronic energy restriction on weight loss in premenopausal women: preliminary results from a randomised pilot trial to reduce breast cancer risk (2007) (0)
- Obesity at age 20 and weight gain during adulthood increase risk of total and premature all-cause mortality: findings from women attending breast screening in Manchester (2023) (0)
- 39. Associations between somatically altered genes and recurrence outcomes in estrogen receptor positive breast cancer (2022) (0)
- Abstract ES02-2: Who should receive preventive therapy? (2013) (0)
- Worldwide Performance of a Methylation Biomarker for Cervical Precancer and Cancer Diagnosis (2020) (0)
- The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation (2017) (0)
- The effect of intermittent v. chronic energy restriction on weight loss and markers of chronic disease risk in premenopausal women: a randomised pilot trial (2009) (0)
- Mass screening by flexible sigmoidoscopy (2002) (0)
- The importance of long-term follow up of participants in clinical trials (2022) (0)
- Abstract P2-08-04: Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET) (2019) (0)
- PD-0123 ANDROGEN RECEPTOR FISH ASSAY PREDICTS POOR SURVIVAL IN EARLY HUMAN PROSTATE CANCER (2012) (0)
- Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study. (2019) (0)
- Editorial comment. (2014) (0)
- Abstract P4-08-01: Not presented (2018) (0)
- Abstract P2-08-12: Integration of tumor size and grade with the breast cancer index (BCI) for prediction of distant recurrence in hormone receptor-positive breast cancer with 1-3 positive lymph nodes (2016) (0)
- Erratum: Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males (2011) (0)
- General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey (2017) (0)
- Application of active surveillance threshold to series of samples submitted for commercial testing. (2016) (0)
- Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds (2018) (0)
- Confounding in epidemiological studies (1992) (0)
- Abstract PD04-08: Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of ‘intermediate grade’ disease and gives clinically meanignful information. (2012) (0)
- Abstract P3-07-01: Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinomain situ: Results from the UK/ANZ DCIS trial: (2016) (0)
- 430 Cell cycle progression genes differentiate indolent from aggressive prostate cancer (2012) (0)
- Tamoxifen f or t he P revention o f B reast C ancer: Psychosocial I mpact o n W omen P articipating i n T wo Randomized C ontrolled T rials (2001) (0)
- Abstract P5-06-15: Computer extracted features of nuclear shape, orientation disorder and texture from H&E Whole slide images are associated with disease-free survival in ductal carcinoma in situ (DCIS) (2020) (0)
- Adherence to a Diet and Exercise Weight Loss Intervention amongst Women at Increased Risk of Breast Cancer~!2009-07-01~!2009-08-06~!2010-07-13~! (2010) (0)
- Degree of similarity within several binomial samples: a measure and test thereof (1978) (0)
- Abstract 4216: Adiponectin, leptin and breast cancer in high risk postmenopausal women: Results from a nested case-control study (2018) (0)
- SemiautomatedDetectionof HumanPapillomavirus DNA of Highand Low OncogenicPotentialin CervicalSmears (1994) (0)
- Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer (2017) (0)
- Evidence based answers to critical questions on cancer screening and prevention (2012) (0)
- Long Term Outcome in a Biopsy Cohort of 988 Conservatively Treated Prostate Cancers. Evidence for Revised Gleason Grading and Use of the Worst Scoring Core (2015) (0)
- Abstract 1614: Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer (2016) (0)
- Tamoxifen for breast-cancer prevention. Authors' reply (2003) (0)
- Markers for the identification of late breast cancer recurrence (2015) (0)
- NHS Economic Evaluation Database and Health Technology Assessment search filter (2016) (0)
- Abstract P5-08-03: Prognostic impact of the combined risk groups by breast cancer index and HOXB13/IL17BR ratio in hormonal receptor positive, node negative breast cancer: A TransATAC study (2016) (0)
This paper list is powered by the following services:
Other Resources About Jack Cuzick
What Schools Are Affiliated With Jack Cuzick?
Jack Cuzick is affiliated with the following schools:
